-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 10, 2021, Syethekine announced the completion of US$107.
5 million in Series B financing
.
The core product of Synthekine is a new generation of IL-2 mutant STK-012
.
At the AACR meeting in 2021, Synthekine reported on the research progress of STK-012
.
IL-2 has been used clinically since the 1990s, but it failed to play an important role due to its high toxicity
.
Professor Christopher Garcia's research on the bias mechanism of IL-2 receptors found that different receptors mediate different physiological effects.
Since then, IL-2 mostly follows the direction of increasing the affinity of IL-2Rβ and decreasing the affinity of IL-2Rα
.
Synthekine believes that these biased IL-2 still have insufficient activity and toxicity
.
Synthekine's STK-012 mainly targets antigens to activate CD8 T cells, but does not act on NK cells and Naive CD8 T cells
.
STK-012 avoids acting on NK cells and Naive T cells to avoid toxicity, and targeting antigens to activate CD8 T cells can more specifically enhance anti-tumor activity
.
In other words, Syethekine is not simply based on IL-2Rα and IL-2Rβ for biased screening, but based on different immune cells to screen specific IL-2 mutants
.
The safety of STK-012 has been confirmed in mouse experiments.
IL-2 and other biased IL-2 will cause mouse death, but STK-012 will not
.
In terms of anti-tumor activity, STK-012 is significantly better than IL-2 and other biased IL-2
.
The editor concluded that Synthekine's STK-012 has a unique mechanism of action, which is expected to further tap the potential of IL-2
.
Syethekine's work also improves the molecular design of cytokines from receptor bias to targeted cell bias, which is equally important for the development of other cytokines
.
The copyright statement welcomes personal forwarding and sharing
.
Any other media or website that needs to reprint or quote the copyrighted content of this website must be authorized and marked "Reprinted from: Bai Aogu" in a prominent position
.
5 million in Series B financing
.
The core product of Synthekine is a new generation of IL-2 mutant STK-012
.
At the AACR meeting in 2021, Synthekine reported on the research progress of STK-012
.
IL-2 has been used clinically since the 1990s, but it failed to play an important role due to its high toxicity
.
Professor Christopher Garcia's research on the bias mechanism of IL-2 receptors found that different receptors mediate different physiological effects.
Since then, IL-2 mostly follows the direction of increasing the affinity of IL-2Rβ and decreasing the affinity of IL-2Rα
.
Synthekine believes that these biased IL-2 still have insufficient activity and toxicity
.
Synthekine's STK-012 mainly targets antigens to activate CD8 T cells, but does not act on NK cells and Naive CD8 T cells
.
STK-012 avoids acting on NK cells and Naive T cells to avoid toxicity, and targeting antigens to activate CD8 T cells can more specifically enhance anti-tumor activity
.
In other words, Syethekine is not simply based on IL-2Rα and IL-2Rβ for biased screening, but based on different immune cells to screen specific IL-2 mutants
.
The safety of STK-012 has been confirmed in mouse experiments.
IL-2 and other biased IL-2 will cause mouse death, but STK-012 will not
.
In terms of anti-tumor activity, STK-012 is significantly better than IL-2 and other biased IL-2
.
The editor concluded that Synthekine's STK-012 has a unique mechanism of action, which is expected to further tap the potential of IL-2
.
Syethekine's work also improves the molecular design of cytokines from receptor bias to targeted cell bias, which is equally important for the development of other cytokines
.
The copyright statement welcomes personal forwarding and sharing
.
Any other media or website that needs to reprint or quote the copyrighted content of this website must be authorized and marked "Reprinted from: Bai Aogu" in a prominent position
.
